Acorda Announces Long-Term Safety Data for CVT-301

Share

(March 29, 2017) - Acorda Therapeutics, Inc. today announced results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson’s that showed no differences in pulmonary function between the group receiving CVT-301 and an observational control group. Read more

Click for a printer friendly version

Back to top